LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

LIGAND PHARMACEUTICALS INCORPORATED Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $47.17 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-27

• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $47.17, a 24.76% increase from fiscal 2024.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $37.81, a 3.17% increase from fiscal 2023.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $36.65, a 26.82% increase from fiscal 2022.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $28.90.